Pasithea Therapeutics Corp.
Novel therapeutics for neurological disorders including oncology, genetic diseases, neurodegenerative disease, and psychiatric conditions
- Sector
- Biotech
- Headquarters
- MIAMI BEACH, FL
- Founded
- 2020
- Latest Form D
- $30.4M, Dec 2021
- Total capital
- $31.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $31.8M
- 3 Form D · last Dec 2021
- 59 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 18 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$30.4M
- Private capital raisedForm D · SEC · 2nd filing$1.2M
- Private capital raisedForm D · SEC · 1st filing$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Craig Maxx AuringerExecutive Officer, DirectorNamed in SEC Form D filings
- Emer Dos Reis LeahyDirectorNamed in SEC Form D filings
- Israel Maxx AbramowitzExecutive Officer, DirectorNamed in SEC Form D filings
- Lawrence Reis SteinmanDirectorNamed in SEC Form D filings
- Simon DumesnilDirectorNamed in SEC Form D filings
- Stanley M. GlossExecutive OfficerNamed in SEC Form D filings
Show all 9 people
- Tiago Andre Dos Reis MarquesExecutive Officer, DirectorNamed in SEC Form D filings
- Tiago Reis MarquesDirectorNamed in SEC Form D filings
- Yassine BendiabdallahExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 18- PendingANTI-ALPHA5 Integrin Antibodies And Uses ThereofUSPTOApplication 19128097
- PendingSolid Forms Comprising (5R,6S)-10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE, And Compositions Comprising And Methods Of Using The SameUSPTOApplication 19559551
- PendingAlpha 5 Beta 1 Integrin Binding Agents And Uses ThereofUSPTOApplication 18559703
Show all 18 patent records
- ANTI-ALPHA5 Integrin Antibodies And Uses ThereofJul 9, 2026 · Application 19128097Pending
- Solid Forms Comprising (5R,6S)-10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE, And Compositions Comprising And Methods Of Using The SameJul 9, 2026 · Application 19559551Pending
- Alpha 5 Beta 1 Integrin Binding Agents And Uses ThereofAug 22, 2024 · Application 18559703Pending
- Tablet Formulations And Uses ThereofApplication 63815358Pending
- ANTI-ALPHA5 Integrin Antibodies And Uses ThereofApplication PCTUS2025026592Pending
- Tablet Formulations And Uses ThereofApplication 63744073Pending
- 10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE Stereoisomers, And Compositions Comprising And Methods Of Using The SameApplication PCTUS2025010070Pending
- Solid Forms Comprising (5R,6S)-10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE, And Compositions Comprising And Methods Of Using The SameApplication PCTUS2025010064Pending
- Solid Forms Comprising (5R,6S)-10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE, And Compositions Comprising And Methods Of Using The SameApplication 63722522Pending
- 10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE Stereoisomers, And Compositions Comprising And Methods Of Using The SameApplication 63722523Pending
- ANTI-ALPHA5 Integrin Antibodies And Uses ThereofApplication 63640147Pending
- 10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE Stereoisomers, And Compositions Comprising And Methods Of Using The SameApplication 63618167Pending
- ANTI-ALPHA5 Integrin Antibodies And Uses ThereofApplication PCTUS2023079345Pending
- ANTI-ALPHA5 Integrin Antibodies And Uses ThereofApplication 63424820Pending
- Alpha 5 Beta 1 Integrin Binding Agents And Uses ThereofApplication PCTUS2022028520Pending
- 10,11-DIFLUORO-12-((2-FLUORO-4-IODOPHENYL)AMINO)-5,6-DIHYDROXY-4,5,6,7-TETRAHYDRO-1H-SPIRO[BENZO[B][1,5,4]OXATHIAZECINE-3,1'-CYCLOPROPANE] 2,2-DIOXIDE Stereoisomers, And Compositions Comprising And Methods Of Using The SameApplication 19603481Pending
- Tablet Formulations And Uses ThereofApplication PCTUS2025056686Pending
- Tablet Formulations And Uses ThereofApplication 63854343Pending
Related companies, and why
- Contineum TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Pulmatrix Operating Company, Inc.Similar federal contract value in Biotech · null in contracts
- Tarsa Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Athos Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- STEM CELL THERAPEUTICS CORPSimilar federal contract value in Biotech · null in contracts
- Guardian Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .